Canada Research Roundup: Emera, Keyera, Oncolytics Biotech

Keyera

24/05/2023 08:16

May 24 (Reuters) - Securities analysts revised their ratings and price targets on several Canadian
companies, including Emera, Keyera and Oncolytics Biotech on Wednesday. 
    
    HIGHLIGHTS   
                 * Emera Inc  EMA.TO : Credit Suisse raises target price to C$60 from C$55 
 
                 * Keyera Corp  KEY.TO : Credit Suisse cuts target price to C$39 from C$39.5 
 
                 * Oncolytics Biotech Inc  ONC.TO : Jonestrading initiates coverage with buy rating;
 PT C$9 
 
        
Following is a summary of research actions on Canadian companies reported by Reuters on Wednesday. Stock entries
are in alphabetical order. 
    
                 * Emera Inc  EMA.TO : Credit Suisse raises target price to C$60 from C$55 
 
                 * Exro Technologies Inc  EXRO.TO : Atb Capital Markets cuts target price to C$3.25 from C$3.3 
 
                 * Keyera Corp  KEY.TO : Credit Suisse cuts target price to C$39 from C$39.5 
 
                 * Oncolytics Biotech Inc  ONC.TO : Jonestrading initiates coverage with buy rating; PT C$9 
 
                 * Rubicon Organics Inc  ROMJ.V : Haywood Securities cuts target price to C$1.75 from C$2.25 
 
    

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))